Table 3.
Top 20 medications that contributed to the anticholinergic burden score in dementia patients with high exposure prior to 2–10 years of dementia according to the scales
| Drug | Total (N = 1,324) | KABS (N = 916) | ACB (N = 975) | ||||
|---|---|---|---|---|---|---|---|
| Number of patients (%) | Average DDD per patient per year | score | Contribution to high exposure (%) | score | Contribution to high exposure (%) | ||
| chlorpheniraminea, b | 1,297 | (98.0) | 17 | 3 | 5.8 | 3 | 5.2 |
| tramadola | 1,262 | (95.3) | 9.2 | 2 | 2.3 | 0 | 0 |
| cimetidinea, b | 1,260 | (95.2) | 46.7 | 2 | 11.6 | 1 | 4.0 |
| diazepama, b | 1,198 | (90.5)) | 34.8 | 1 | 4.2 | 1 | 3.4 |
| ranitidinea, b | 1,150 | (86.9) | 28.6 | 1 | 3.1 | 1 | 3.0 |
| hydrochlorothiazideb | 974 | (73.6) | 80.2 | 0 | 0 | 1 | 10.1 |
| alprazolama, b | 921 | (69.6) | 32.5 | 1 | 4.1 | 1 | 3.2 |
| dimenhydrinatea, b | 869 | (65.6) | 33.3 | 3 | 11.3 | 3 | 11.7 |
| amitriptylinea, b | 727 | (54.9) | 10.9 | 3 | 3.8 | 3 | 3.4 |
| theophyllinea, b | 664 | (50.2) | 13.8 | 1 | 1.5 | 1 | 1.5 |
| furosemidea, b | 606 | (45.8) | 39.5 | 1 | 4.3 | 1 | 5.0 |
| atenololb | 549 | (41.5) | 33 | 0 | 0 | 1 | 4.3 |
| lorazepama | 515 | (38.9) | 11.9 | 1 | 1.5 | 0 | 0 |
| nifedipineb | 459 | (34.7) | 38 | 0 | 0 | 1 | 5.2 |
| triazolama | 454 | (34.3) | 15.8 | 1 | 2.1 | 0 | 0 |
| octylonium bromidea | 451 | (34.1) | 4.5 | 3 | 1.8 | 0 | 0 |
| tolterodinea, b | 355 | (26.8) | 7.9 | 3 | 2.7 | 3 | 2.8 |
| propiverinea, b | 342 | (25.8) | 6.3 | 3 | 2.2 | 3 | 2.2 |
| isosorbideb | 290 | (21.9) | 40.2 | 0 | 0 | 1 | 5.4 |
| doxazosinb | 263 | (19.9) | 18.1 | 0 | 0 | 1 | 2.4 |
| digoxinb | 215 | (16.2) | 13.3 | 1 | 1.2 | 1 | 1.7 |
| paroxetinea, b | 209 | (15.8) | 9.3 | 2 | 2.1 | 3 | 3.5 |
| quinupraminea | 188 | (14.2) | 5.1 | 3 | 2.2 | 0 | 0 |
| solifenacina, b | 174 | (13.1) | 6.1 | 3 | 2.1 | 3 | 2.3 |
| levodopa and decarboxylase inhibitora | 166 | (12.5) | 12.6 | 1 | 1.8 | 0 | 0 |
| beztropineb | 77 | (5.8) | 3.6 | 3 | 1.4 | 3 | 1.3 |
| amantadinea | 76 | (5.7) | 6.3 | 2 | 1.8 | 2 | 1.1 |
DDD Defined daily dose, KABS Korean Anticholinergic Burden Scale, ACB Anticholinergic Cognitive Burden
aTop 20 medications to contribute to anticholinergic burden in high exposure group with KABS
bTop 20 medications to contribute to anticholinergic burden in high exposure group with ACB